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ABSTRACT 
The in vivo effects of Ftorafur (FT) and 5-
fluorouracil (FU) were evaluated at several different 
organizational levels within the same animal model. On 
a molar basis, FU was found to be two to three times 
more potent than FT with respect to growth inhibition 
of murine mammary adenocarcinomas. However, administra-
tion of FT produced less host toxicity at a dose level 
" which resulted in similar antitumor activity. Drug-
induced perturbations in cell cycle phase distributions 
were analyzed by the flow cytometer (FCM). Although 
FCM analysis is limited by the lack of information on 
the extent of dead and dying cells, data obtained with 
both drugs were consistent with the possibility of S 
phase cytotoxicity and drug-induced GI/S block or delay. 
Changes in the age distribution of perturbed tumor cells, 
as detected by FCM analysis, correlated with 3H- TdR 
autoradiography and with 32p incorporation into DNA but 
not with 3H-deoxyuridine incorporation into DNA. Both 
drugs depressed 3H-deoxyuridine incorporation into DNA; 
however, incorporation in both the tumor and small in-
testine returned to control levels earlier with FT than 
with an equimolar dose of FU. However, both drugs pro-
duced similar patterns of 3H-deoxyuridine incorporation 
when FT was administered at three times the molar equiva-
lent dose of FU. The results of these studies also 
suggest that deoxyuridine incorporation primarily re-
flects drug effects on thymidylate synthetase and not 
necessarily the overall ~ate of DNA synthesis. 
This study also involved the development of 
techniques for the dispersal of solid tumors and intes-
tinal lining epithelium into single cell suspensions 
for FCM analysis. Tetraphenylboron (TPB) was utilized 
as an aid to solid tumor dispersal. TPB-dispersed 
tumors yielded DNA distributions with minimal cell 
clumping and low levels of cellular debris. Fluores-
cent enzyme histochemistry with subsequent FCM analy-
sis was utilized to separate dispersed epithelial cells 
of the small intestine into crypt and villus subpopula-
tions. When fully optimized, the epithelial cell separ-
ation should offer a rapid method by which perturbations 
-in the age distribution of crypt cells can easily be 
evaluated by FCM. 
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INTRODUCTION 
5-Fluorouracil (FU) is a fluorinated pyrimidine 
antimetabolite which has been used in the treatment of 
both experimental animal tumors and human malignant 
disease (1-8) Q FU has been widely employed in the treat-
ment of metastatic colorectal cancer (8, 9) and is cur-
rently a component of several combination therapeutic 
schedules for treatment of metastatic carcinoma of the 
breast (10, 11, 12) and gastrointestinal cancer (13). 
The rationale for the development of fluorinated pyri-
midines as chemotherapeutic agents arose from the obser-
vation that a chemically-indu~ed rat hepatoma utilized 
uracil for nucleic acid biosynthesis to a greater extent 
than did normal rat liver (14). FU was synthesized (15) 
as an antimetabolite which closely resembled uracil in 
structure but differed in the substitution of a stable 
fluorine atom for a hydrogen atom at carbon-S of the 
pyrimidine ring. It was thought that FU might be pre-
ferentially utilized by tumors and, therefore, exert a 
specific antitumor effect. Although absolute specificity 
has not been achieved, it was later shown that FU and 
other fluorinated pyrimidines, e.g., 5-fluorouridine(FUR), 
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5-fluoro-2'-deoxyuridine (FUdR), do have clinically use-
ful antitumor activity (l)e 
Several laboratories have investigated the bio-
chemical and pharmacological effects of the fluorinated 
pyrimidines (1, 3,16,17, lS)e Pyrimidine analogs are 
transformed to the nucleotide stage via pyrophosphory-
lase or phosphorylase plus kinase reactions~ They are 
then substituted for normal pyrimidines in the various 
metabolic reactions of the cell. As illustrated in the 
diagram in Figure 1, the biochemical effects of FU in 
the anabolic pathway are three-fold. First, FU inhibits 
the incorporation of uracil and orotic acid into RNA 
(19, 20). Second, FU can be metabolized to the nucleo-
side triphosphate level and then be incorporated into 
fraudulent RNA (19, 20, 21). It has been suggested that 
incorporation of fluorinated pyrimidines into RNA may 
result in mispairing or miscoding, thus producing 
"phenotypic mutations" (22). Third, the active metab-
olite of FU, 5-fluoro-2'-deoxyuridine-5'-monophosphate 
(FdUMP), inhibits DNA synthesis by blocking thymidylate 
synthetase (17, 19, 23), the enzyme which catalyzes the 
formation of thymidylate from deoxyuridylate. Neither 
FU or its metabolites are incorporated into DNA (24). 
Although recent studies have indicated that FU and its 
metabolites may also affect other aspects of nucleic 
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acid biosynthesis, such as inhibition of ribosomal RNA 
maturation (25, 26), the inhibition of thymidylate syn-
thetase is believed to be the major locus of the anti-
tumor activity of FU (27, 28). 
The excretion, distribution, and metabolism of 
radioactively-labeled FU have been extensively studied 
in both animals and human patients (20, 21, 29, 30, 31). 
The initial steps of FU degradation, i.e., the conver-
sion to dihydrofluorouracil, a-fluoro-S-ureido-
propionic acid, a-fluoro-S-alanine, a-fluoro-S-
quanidopropionic acid ana CO2 are exactly analogous to 
those for uracil (32). In addition, FU is extensively 
converted to urea in human patients (29). These degra-
dative products lack antitumor activity (31). The 
liver, which is the principal site of FU catabolism (29), 
will catabolize FU up to a threshold dose, above which 
anabolism proceeds. In humans, approximately 60-80% of 
an intravenous dose of FU is excreted as respiratory 
CO2 in 8-12 hours (31), and approximately 15% is ex-
creted in the urine in 6 hours as unchanged drug (30). 
Therefore, only a small percent of the administered dose 
follows the anabolic pathway. 
The goal of most treatment schedules is to des-
troy the tumor population without causing irreversible 
damage to the normal proliferating cells. In addition 
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to biochemical factors, the effectiveness of many of the 
antitumor agents may be influenced by the proliferating 
status of the tumor versus normal cell populations. 
Knowledge of the cell kinetics of the tumor, in conjunc-
tion with information about the cell-killing character-
istics of the antitumor agent, can be used to design 
effective drug combinations and treatment schedules. 
For example, an agent that may selectively kill cells 
in the DNA synthetic phase of the cell cycle could be 
combined with a treatment modality that is more cytotoxic 
for cells in other phases of the cycle. This approach 
was successfully utilized by Nitze et ale in human solid 
tumors (33). Treatments based on cell cycle kinetic 
principles have been particularly useful in patients with 
acute lymphoblastic leukemia (34, 35, 36). 
Cell cycle studies originated with the work of 
Howard and Pelc in 1951 (37) I which documentated the 
presence of a DNA synthesis period (S phase) in the 
growth cycle of cells. The cell cycle can be divided 
into discrete phases: Gl , S, G2 , and mitosis (M), the 
duration of which can be determined by the percent 
labeled mitosis of Quastler and Sherman (38). These 
phases are characterized by specific biochemical and 
molecular events. RNA and protein synthesis are neces-
sary for cell progress through the Gl period (39,40). 
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The levels of specific enzymes necessary for DNA repli-
cation, such as thymidine kinase, have been shown to 
increase during Gl phase (41). There is evidence that 
regulation of cell proliferation in a particular tissue 
is governed by lengthening or shortening the Gl period 
(42). The Gl to S phase transition is probably brought 
about by an initiator protein whose production is reg-
ulated by RNA synthesis (43). S phase is the period of 
DNA replication. Ribonucleotide reductase activity 
rises at the beginning of S phase, whereas other enzymes 
involved in pyrimidine deoxyribo~ucleotide synthesis in-
crease later in S (44). The G2 period, which is rela-
tively short compared to other phase durations, is usually 
assumed to be necessary for chromosome condensation and 
mitotic assembly. During M ~he parent cell divides to 
produce daughter cells. There is a decrease in protein 
synthesis (45) and cessation of RNA synthesis during 
mitoses (45, 46). 
In the majority of tissues, certain cell sub-
populations exist in a "resting" or quiescent stage in 
which they retain their proliferative capacity but do 
not actually replicate. The growth fraction of a tissue, 
such as a tumor, is a term introduced by Mendelsohn (47) 
to describe the fraction of proliferating cells in the 
population. The drug sensitivity of quiescent. cells may 
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be different than that for rapidly proliferating cells. 
Investigations with the model of Bruce et ale (48) 
with haematopoietic stern cells have indicated that 
resting cells are less sensitive to cytotoxic agents 
than are cycling cells (18, 49). Although a reverse 
relationship has been observed with particular drugs, 
e.g., bleomycin and BCNU, in other model systems it is 
generally believed that a low growth fraction of a tumor 
may influence the apparent effectiveness of an antitumor 
agente Another important cell kinetic parameter which 
may be utilized in designing che~otherapy schedules is 
that of recruitment, a term used to designate the induc-
,tion of resting cells into the proliferating cycle. Re-
cruitment can result from depletion or killing of the 
proliferating population of a tumor, such as occurs with 
radiation (50) and chemotherapy (51, 52). Schabel (53) 
successfully utilized low-dose therapy in a solid tumor 
to kill proliferating cells and recruit the resting pop-
ulation for subsequent chemotherapy. Therefore, infor-
mation about the cell killing characteristics 'of a 
particular agent can potentially be utilized to predict 
optimal drug combination and schedules for maximum anti-
tumor activity. 
Chemotherapeutic agents can be subdivided into 
two general categories based on their cytotoxic charac-
teristics. The cell cycle stage specific agents (CCSS) 
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kill cells only when they are present during the sensi-
tive phase of the cycle. Drugs, such as vinblastine, 
amethopterin, and azaserine, are included in this class 
(54)e The cell cycle stage nonspecific drugs (CCSN) 
kill cells in all phases of the cycle to a similar 
extent and are less cytotoxic for cells in a nonpro-
liferating state. These drugs include actinomycin D, 
nitrogen mustard, and cyclophosphamide (54) 0 Although 
FU is generally believed to be a CCSN agent (54, 55), 
there is evidence that its metabolites, FUR and FUdR 
may be CCSS. Several investigators (54, 56) have re-
ported that FU is equally cytotoxic in all parts of 
the cycle and that the sensitivity of the cell popula-
tion depends strongly upon the fraction of the popula-
tion in the proliferative state (54). In vitro studies 
of Bhuyan et al. (56) indicated that FUdR kills cells 
preferentially in S phase, whereas Lozzio (57) found 
that it was cytotoxic to cells in both Gl and S. Cells 
in M were relatively insensitive to FUdR (57). The 
majority of these studies on the cell cycle stage 
specificity of FU and its metabolites were done with 
in vitro model systems. The effect of FU on mammal-
ian cell cycle kinetics has not been extensively in-
vestigated with in vivo animal models. Information 
obtained from such studies could be useful in the 
planning of rational therapeutic regimens which might 
be more effective than currently used protocols. 
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FU, like most of the clinically useful anti-
tumor agents, has a low therapeutic index. Toxicity to 
normal tissues, such as the bone marrow and gastroin-
testinal tract, is the major limiting factor in the 
clinical usefulness of FU. Stomatitis, nausea, vomiting, 
diarrhea, and leukopenia are common side effects of FU 
therapy (58-62). As a result, much effort has been 
spent in the development of chemotherapeutic analogs of 
FU which, hopefully, would display improved therapeutic 
indices. Ftorafur ([S-fluoro-l-(tetrahydro-2-furyl) 
uracil] [FT]), a tetrahydrofuran-containing pseudonucle-
aside analog of FU, was synthesized in the Soviet Union 
in 1965 (63) as part of a program designed to study the 
antitumor activity of nucleosides containing a variety 
of sugar and heterocyclic moieties. Subsequent studies 
on the pharmacological activity of FT indicated that it 
was less toxic and possessed equal or greater antitumor 
activity than FU (64-67). Initially, limited quantities 
of FT in the United States restricted investigation of 
its properties in this country. However, in 1972, Earl 
and Townsend (68) at the University of Utah developed 
a rapid and efficient method for the synthesis of FT and, 
consequently, large quantities of drug became available 
for basic and clinical studies in this country. 
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The principal advantage of FT, as compared to 
FU, was reported to be lower toxicity, with retention 
of the same antineoplastic effect. Hrsak et al. (69) 
reported that mice treated with FT showed less reduc-
tion and faster recovery of haematopoietic stem cells 
than after a comparable dose of FU. In recent studies, 
FT, as a single treatment in mice, was half as toxic as 
FU on an mg/kg basis but not on a molar basis (70). FT 
was less suppressive to both cell-mediated and humoral 
immunity than was FU 970). A number of clinical trials 
have also suggested that 'FT was less myelosuppressive 
'than FU, yet was still effective against solid tumors 
'(65, 68). Clinically, FT, like FU, appears most ef-
fective against breast (64, 65, 71-73) and gastroin-
testinal cancer (64, 74, 75). Recent reports on ex-
perimental tumor models have indicated that FT and FU 
may have slightly different antitumor spectra (76). 
Biochemical and pharmacological studies with 
FT suggested that ~t acted as a depot form of FU and 
must be metabolically activated (77, 78). FT is me-
tabolized in vivo to FU and other known fluorinated 
pyrimidine metabolites (77, 79-82). It is fairly evenly 
distributed to liver, small intestine, kidney, spleen, 
and brain (79). The liver contains the highest initial 
proportions of FU and its metabolites and may be the 
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primary site at which FU is released in vivo. In rats, 
the half-life of FT in plasma was estimated to be ap-
proximately 5-6 hours, whereas the half-life of FU was 
between 10 and 30 minutes (79). 
The studies reported in the following sections 
are a comparison of the in vivo effects of FU and FT 
in tumors and in normal proliferating tissue of mice. 
Drug effects were examined at the whole animal, tissue, 
cellular, and molecular levels. Varying doses and 
treatment protocols were utilized to obtain information 
about the efficacy of FT'versus FU with respect to growth 
inhibition of murine mammary adenocarcinomas. Changes 
in mouse body weight were also monitored during each 
therapeutic regimen in an effort to compare the extent 
of host toxicity produced by each drug. 
Although FU has been used clinically for several 
years, its in vivo effects on mammalian cell cycle ki-
netics have not been clearly documented. Since FT is 
a relatively new drug, there are even fewer detailed 
studies on its in vivo effects, and no information is 
available on drug-induced cell cycle perturbations. As 
seen from the previous discussion on cell kinetics, such 
information should be potentially useful in planning 
effective treatments. 
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In this study, drug-induced cell cycle pertur-
bations were examined by standard autoradiographic pro-
cedures and by the flow cytometer (FCM). The FCM is an 
instrument which rapidly determines the distribution of 
cells throughout the cell cycle by measuring the DNA con-
tent of individual cells. Cells in suspension are 
stained with a fluorescent dye such as acriflavin or 
chromomycin. The amount of fluorescence in an individual 
cell is directly proportional to its DNA content. The 
FCM will detect and analyze the DNA-specific fluores-
cence and display the cell cycle_phase distribution of 
the population in the form of a histogram. The fraction 
of the cell population in GI , Sand G2 + M can then be 
calculated. The advantage of the FCM over standard 
autoradiographic procedures lies in the rapid analysis 
of cell cycle phase distributions. Since as many as 
a million cells can easily be analyzed within a few 
minutes, data obtained by FCM are more statistically 
reliable than those obtained by autoradiography. In 
addition, unlike autoradiography, FCM analysis yields 
direct information about cell phase distributions, even 
in the presence of agents which interfere with DNA syn-
thesis. 
FCM analysis of drug-induced cell cycle changes 
can easily be performed on in vitro cell cultures (83, 
84)e These single cell suspensions contain negligible 
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amounts of cellular debris and provide DNA distributions 
which can readily be analyzed as a result of the low 
level of background fluorescence. However, it is ad-
vantageous to evaluate drug effects on animal tumors 
in vivo, which more closely approximate the clinical 
situation and, thus, may be more appropriate models for 
studying the cell cycle effects of chemotherapeutic 
agents. FCM analysis of DNA distributions of cells ob-
tained from solid tissues necessitates the development 
of cell dispersal, separation, and isolation procedures. 
In the present study, sodium tetraphenylboran (TPB), a 
potassium-complexing reagent reported to aid in the dis-
persal of liver cells (85), was used successfully with 
solid tumors (~6). 
Since many of the cli~ically useful cancer chemo-
therapeutic agents exert effects on both tumor and nor-
mal tissue, it is desirable to evaluate drug-induced 
cell cycle changes in both types of tissue. Drug tox-
icity in the small intestine is one of the major limit-
ing factors in therapeutic protocols. Cell cycle per-
turbations in the proliferating cells of the small 
intestine, the crypts, are usually studied with tedious 
and time-consuming autoradiographic techniques. In order 
to utilize FCM for analysis of the age distribution of 
the proliferating cells of the small intestine, it would 
13 
be necessary to obtain a suspension of pure crypt cells. 
Most of the presently available procedures for obtaining 
so-called "crypt" preparations yielded mixed populations 
of both crypt and villus epithelial cells. Therefore, 
a method to separate crypt and villus cells with the 
FCM on the basis of fluorescent enzyme histochemistry 
was developed. 
In vivo effects of FU and FT were also examined 
at the molecular level by monitoring the incorporation 
of tritiated deoxyuridine and Na 2H
32po4 incorporation 
into DNA. These data were correlated with those obtained 
at the tissue and cellular levels in the hope that such 
information will prove useful clinically in planning and 
evaluating effective chemotherapeutic regimens with these 
agents .. 
MATERIALS AND METHODS 
Mice and Tumors 
C3H mice of both sexes, 8-12 weeks old, were 
utilized in all studies. Mammary tumors from the es-
tablished Sl02F and Slow lines were used (87, 88). 
These lines were developed from adenocarcinomas which 
arose spontaneously in breeding female C3H mice. The 
Sl02F tumor has a doubling time of approximately 2 
days, a growth fraction of 55%, and a generation time 
of 17 hours (87). The Slow tumor has a doubling time 
of 5-6 days, a growth fraction of 25%, and a generation 
time of 33 hours (87). The lines were maintained by 
subcutaneous trochar transplants of 1-2 mm pieces of 
tumor into both flanks of ether-anesthesized animals. 
Tumor growth was followed serially by caliper measure-
ments in three dimensions. Tumor volume was estimated 
by a herni-ellipsoid approximation with a correction for 
skin thickness (89). 
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Drugs 
FU (Sigma) and FT (prepared in the laboratory 
of Dr. L.B. Townsend) were administered by intraperi-
toneal injection into unanesthesized mice between 7:00 
and 9:00 a.m. All drug solutions were freshly pre-
pared immediately before use and were injected in a 
volume of 0.01 ml/gm body weight. FU was dissolved in 
0.9% NaCl solution. FT was dissolved in either 0.9% 
NaCl solution for the 100 mg/kg dose or with slight 
heating in 0.2 M sodium carbonate buffer, pH 9.4 for 
the 300 mg/kg dose. Sterile 0.9% NaCl solution or 
carbonate buffer was injected into control animals. 
All drug treatment studies were begun when the tumor 
volume was approximately 200 ~i (+ 50 ~i). Body weight 




Into Deoxyribose Nucleic 
Acid (DNA) 
Deoxyuridine [6-3H] (3H- UdR New England Nuclear: 
100 ~Ci/kg, S.A. 21 ~Ci/~mole was administered by intra-
peritoneal injection at 1-96 hours after drug treatment. 
Mice were killed 30 minutes thereafter by cervical dis-
location and tumors and small intestine were quickly 
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removed. The tumors and small intestine were rinsed 
with 0.9% NaCl solution, frozen between two blocks of 
dry ice and stored at -20°C for subsequent analysis. 
Nucleic acids were extracted according to the phenol 
procedure of Morley and Kingdon (90). Briefly, the 
tissue was homogenized on ice in either 7 ml (tumor) 
or 15 ml (intestine) of 1% 8-anilino-l-napthalene-
sulfonic acid sodium salt (tech.) (Eastman Kodak) dis-
solved in 0.2 M acetate buffer, pH 7.0. Five ml of 
the homogenate was mixed with 5 ml of 88% (w/v) liqui-
fied phenol (Mallinckrodt) and centrifuged at 18,000 xg 
for 20 minutes. The clear supernatant was removed, 
and the nucleic acids were precipitated by the addition 
of 1.5 volumes of absolute ethanol. The resulting 
strands were washed once with ice-cold 10% trichloro-
acetic acid (TCA) and once with absolute ethanol. The 
precipitate was then dissolved in 0.5 N perchloric 
acid (PCA) and the nucleic acids were hydrolyzed by 
heating at 90°C for 10 minutes. An aliquot was removed 
for radioactivity determination and the remainder was 
utilized for DNA-deoxyribose determination by means of 
the diphenylamine reaction of Burton (91). Deoxyadeno-
sine served as a standard. Radioactivity was measured 
in a Packard scintillation spectrometer. The efficiency 
of the Triton X-lOa scintillation counting mixture was 
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estimated by internal standardization and was approxi-
mately 25% (+ 5%). Data are expressed as dpm/~mole 
deoxyribose or as percent of control. 
Phosphorus Incorporation 
Into DNA 
32 Na2H P04 (New England Nuclear: carrier free, 
20 ~Ci/mouse) was administered intraperitoneally at 
specific intervals after drug treatment. Thirty min-
utes were allowed for metabolic utilization of the 
labeled precursor. The mice were then killed by cer-
vical dislocation, and the excised tissues were rinsed 
with 0.9% NaCl solution and frozen on dry ice. Nucleic 
acids were isolated according to the procedure described 
above. However, since 32p can be incorporated into 
both ribonucleic acids (RNA) and DNA, the RNA was sep-
arated from DNA by base-catalyzed hydrolysis (92) as 
follows: the washed nucleic acid precipitate was dis-
solved in 0.3 N KOH at 37°C for 2 hours. Ice-cold 1.2 N 
PCA was then added to precipitate potassium perchlorate 
and the unhydrolyzed DNA. The precipitate was washed 
with 0.2 N PCA and the DNA hydrolyzed by heating at 70°C 
for 20 minutes in 0.5 N PCA. DNA-deoxyribose was 
measured by the diphenylamine procedure (91), and radio-
activity was determined by liquid scintillation count-
ing, as described above. The counts per minute were 
18 
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corrected for P decay such that all data were related 
to the original dose of administered 32p. Data are 
expressed as counts per minute (cpm) per ~mole deoxy-
ribose. Measurements of the amount of RNA present in 
the DNA fraction by the orcinol reaction (92) indicated 
that there was less than 7% contamination of the DNA 
fraction with RNA. 
Thymidine Incorporation 
Into DNA 
Thymidine [methyl-3H] (3H- TdR) was utilized for 
both autoradiographic studies and for radioactivity de-
termination by liquid scintillation counting. For 
autoradiography, mice were injected intraperitoneally 
with 3H- TdR (New England Nuclear: 20 ~Ci/mouse, spe-
cific activity 6.7 Ci/rnrnole) and killed at specified 
intervals after injection. Criteria for determining 
labeling indices are described in the next section. 
In experiments in which radioactivity was determined 
by scintillation counting, 3H- TdR (New England Nuclear: 
100 ~Ci/mouse, specific activity 40 ~Ci/~mole) was ad-
ministered intraperitoneally at specified intervals 
prior to sacrifice. The specific activity of the ra-
dioactively-labeled DNA was determined by the procedures 
described above. Results were recorded as DPM per ~mole 
deoxyribose. 
Autoradiography 
Tumors were removed, rinsed with 0.9% NaCl 
solution and fixed in 10% buffered formalin. Duo-
19 
denums were flushed with isotonic saline prior to fix-
ation in a formalin solution (20% v/v formaldehyde, 
70% ethanol, glacial acetic acid; 2:20:1, v/v/v). 
Formalin-fixed tumors and duodenums were embedded in 
Paraplast (Sherwood Medical Industries, Inc.) and 
sectioned at 2-3 ~m. In experiments with single cell 
preparations, the suspensions were placed on glass 
slides, air-dried and fixed in Carnoy's fluid (absolute 
ethanol, glacial acetic acid; 3:1, v/v). The slides 
were dipped in Kodak NTB3 liquid emulsion and exposed 
for 6-60 days, developed with Kodak D19 developer and 
stained with hematoxylin and eosin. To minimize observer 
bias, the slides were coded with random numbers before 
cells were scored as labeled or nonlabeled. A minimum 
of 200 labeled cells were counted. The background 
averaged less than one grain per cell; therefore, cells 
with three or more grains were considered as being 
labeled. 
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Tumor Cell Dispersal 
The TPB dispersal technique has previously 
been published (86). A schematic of the TPB dispersal 
procedure is shown in Figure 2. Tumors with a volume 
of less than 200 ~~ contain minimal amounts of necrotic 
debris and were routinely used to prepare cell suspen-
sions. After the tumor was removed from the mouse and 
halved, any grossly necrotic material was scraped off 
with a glass rod. The tumor was minced in 0.9% NaCl 
solution with a sharp scalpel or scissors and the 
minced tissue transferred to a flask containing 7 ml 
3 mM sodium tetraphenylboron (J.T. Baker), 0.05 M sucrose, 
0.005 M Na 2HP04 , and 0.14 M NaCl. The minced tissue 
was incubated at 37°C with gentle shaking in a recipro-
cating water bath for one minute. Cell debris was often 
found in the incubation fluid after the one minute incu-
bation. Therefore, the initial incubation medium was 
removed and fresh solution added to the tumor fragments; 
this mixture was incubated for 30 minutes. The suspen-
sion was then passed through a plastic syringe (10-15 
times) to completely disperse the remaining tissue frag-
ments. After an additional 30 minutes of incubation, 
the cell suspension was filtered through 37 ~m nylon 
mesh to remove residual clumped cells, and washed three 
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times with 0.14 M NaCl solution. The washed cells were 
then fixed in 10% buffered formalin and stained by an 
acriflavin-Feulgen technique (93) for FCM analysis. 
If 3H- TdR autoradiography was also done, drops of un-
stained single cell suspensions were placed on glass 
slides and air-dried in preparation for dipping in 
photographic emulsion. 
Intestinal Epithelial Cell Isolation 
Intestinal epiethelial cells were isolated from 
C3H mice by the Weiser (94) procedure with the following 
modifications. The entire small intestine was removed 
and flushed with phosphate-buffered saline (PBS: 0.96 M 
Na 2HP04 , 0.29 M NaCl, 0.38 M KH 2P04 , pH 7.2) containing 
1.5 mM dithiothreitol (Sigma). It was then filled with 
a solution containing 1.5 roM KCl, 27 roM sodium citrate, 
96 roM NaCl, 8 mM KH 2P04 , 5.6 roM Na 2HP04 , pH 7.3 (Solution 
A) and each end was tied off with surgical thread. The 
filled intestine was then placed in 0.3 M sucrose and 
incubated at 37°C with gentle agitation for 15 minutes 
in a reciprocating shaker. Solution A was then removed 
and replaced by Solution B (1.5 roM [ethylenedinitrilo]-
tetraacetic acid disodium salt [EDTA], 0.5 roM dithio-
threitol dissolved in PBS). The filled intestine was 
then incubated for 25 minutes, during which time the 
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villus epithelium became detached from the basement mem-
brane and underlying lamina propria. The villus frac-
tion was then collected by flushing the gut with Solution 
B. Fresh Solution B was then added and an enriched crypt 
fraction, containing varying amounts of villus cells, 
was removed during a subsequent 50 minute incubation. 
In later experiments, it was found that a higher cell 
yield could be obtained by everting the intestines prior 
to incubation in Solution A_ 
Intestinal Cell Dispersal 
The crypt fraction obtained by the previously 
discussed isolation procedure consists of single crypt 
and villus cells, with some clumping due to undispersed 
epithelial fragments and to contaminating mucus which 
tends to aggregate the single cells. Cell clumps were 
separated by passing the suspension 15 times through a 
15 g needle, 5 times through a 22 g needle, and subse-
quent filtration through 37 ~m nylon mesh. The cells 
were then washed twice with 30 ml of PBS and resuspended 
in the same solution_ 
Mucus was removed by incubating washed epithel-
ial cells in 2 mg/ml ascorbic acid, 1% hydrogen peroxide, 
and 0.001 M CuS04 -5H 20, pH 7.2, for 20 minutes at 37°C 
(95). The cells were then centrifuged at 500 ~g; mucus 
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was found in the supernatant and along the sides of the 
test tube. The suspension was washed once with PBS to 
remove traces of the mucolytic incubation f·luid and the 
cells were resuspended in PBS. 
Enzyme Histochemical Reaction 
A simultaneous-coupling procedure was used for 
the leucine aminopeptidase reaction (96). The epithelial 
cell suspension was diluted with PBS to a final concen-
tration of approximately 10 7 cells/mI. The enzyme sub-
strate, L-leucyl-4-methoxy-S-napthylamide-HCI (Sigma) 
was initially dissolved in 1-2 drops of dimethylforma-
mide (DMF: Eastman Organic Chemicals) and then diluted 
with 0.2 M morpholinethane sulfonic acid (MES: Sigma), 
pH 6.3, to a final concentration of 0.5 mg/ml. Nitro-
salicylaldehyde (NSA: Eastman Organic Chemicals) was 
prepared in 50% DMF at a concentration of 10 mg/ml. The 
final concentration of NSA in the enzyme incubation mix-
ture was 10 ~g/ml. The NSA solution was freshly pre-
pared immediately before use. One-quarter ml of the 
cell suspension was incubated with 2 ml of the incubation 
mixture (substrate plus NSA) for 30 minutes at 37°C with 
occasional shaking. The cells were then washed once 
with 0.2 M MES at 4°C. Every effort was made to analyze 
the enzymatically-stained cells as soon as possible after 
the enzyme reaction. The samples were maintained at 
4°C prior to FCM analysis. 
Cell Staining for FCM Analysis 
Tumor Cells 
After fixation (at least 24 hours) in 10% 
buffered formalin, TPB-dispersed tumor cells were 
stained by the acriflavin-Feulgen technique (93) for 
24 
FCM analysis. The staining protocol is represented in 
a flow diagram (Figure 3). All centrifuging was done 
at 500 xg for 5 minutes qnd supernatants were removed 
by aspiration. Five mls of each reagent was added to 
the tube with vortexing. Acriflavin (Gurrs) (4 x 10- 4 M) 
was dissolved in 1 part 0.5 N HCl and 9 parts glass-
distilled water. Acid alcohol was prepared by a 1:100 
dilution of concentrated HCl with 70% ethanol. 
Intestinal Epithelial Cells 
Fluorescent enzyme histochemical staining pro-
cedures are discussed in a previous section. DNA 
distributions of mixed epithelial cell populations were 
obtained by staining either with acriflavin (as des-
cribed previously, chromomycin, or Hoechst 33258. 
Chromomycin. Chromomycin staining (97) was done 
on cells fixed in ice-cold 70% ethanol for at least 30 
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minutes. The ethanol-fixed cells were then centrifuged 
at 500 xg for 5 minutes. The supernatant was removed 
by aspiration and the cells were resuspended in 5 ml of 
chromomycin staining solution. The chromomycin staining 
solution consists of 10 mg chromomycin A3 (Calbiochem), 
1.5 g MgC1 2 -6H 20 and 500 ml cold distilled water. After 
staining, the cells were placed in the dark for 20 min-
utes at room temperature prior to FCM analysis. 
Hoechst 33258 staining. A modification of the 
Hoechst 33258 staining protocol described by Latt et ale 
(98) was utilized. The modification included a marked 
reduction in the dye concentration in order to obtain 
nuclear fluorescence with minimal cytoplasmic fluores-
cence. Epithelial cells were fixed in 70% ethanol for 
at least 30 minutes. The cells were then centrifuged 
and resuspended in 2 ml of 0.005 M HEPES (N-2-Hydroxy-
ethylpiperazine-N I -2-ethane sulfonic acid), 0.15 M NaCl, 
pH 7.0 buffer. One-tenth ml of Hoechst 33258 (Dr. H. 
Loewe, Frankfurt, Germany) (0.01 mg/ml dye in Hepes 
buffer) was then added. The final dye concentration 
was 5 x 10-7 M. The cells were allowed to stand at room 
temperature in the dark for at least 15 minutes prior 
to FCM analysis. In experiments in which samples 
dually-stained for leucine aminopeptidase activity and 
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for DNA were needed, the Hoechst staining was performed 
after the enzymatic staining reaction. 
Flow Cytometer 
Tumor DNA Distributions 
The FCM used in these, studies has been previ-
ously described (99) and, therefore, will not be dis-
cussed in detail. The FCM was equipped with a 4-watt 
(all-lines) argon ion laser (Spectra Physics Model 164-05) 
'adjusted to emit 1.0 W at 488 nm. Briefly, acriflavin-
stained cells were passed through a beam of laser light 
and excited at a wavelength of 488 nm, and the resulting 
fluorescence was collected perpendicular to both laser 
beam and flow axis. The fluorescence, which was pro-
portional to DNA content, was projected through a Corning 
3-69 color filter (50 percent transmission at 525 nm) 
onto an RCA 7164 R photomultiplier tube. After the 
photomultiplier output was integrated, amplified, and 
digitized, the data were transferred to magnetic tape 
or computer disc for subsequent analysis. The stability 
of the overall system was repeatedly checked by running 
1.75 ~m fluorescent microspheres (Polysciences, Califor-
nia). DNA distributions were analyzed according to the 
method of Dean et ale (100). 
Intestinal Epithelial Cell 
Analysis 
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The Lawrence Livermore Laboratory flow sorter 
(99), a modified Becton-Dickinson FACS-II model, was 
utilized in the analysis of the chromomycin-stained 
intestinal epithelial cells. The sorter was equipped 
with a 4-watt (all-lines) argon ion laser (Spectra 
Physics Model 171-03) which was adjusted to emit 200 mw 
at 457 nm. The cells emerged from a 100 ~m diameter 
nozzle and intersected the laser beam at 90°. Fluor-
escence was collected perpendicular to both flow axis 
and laser beam and was projected through a filter 
(Corning 3-71) tranmitting light above 480 nm (50 per-
cent transmission point) onto a photomultiplier tube 
(RCA 8575). The pulse processing and storage were the 
same as described above for the FCM. 
For Hoechst 33258-stained cells, the argon ion 
laser was adjusted to emit 300 mw at the 351-364 nm 
doublet. Logarimithic amplification of fluorescence and 
low-angle (0-7°) forward scatter was utilized in the 
two-variable analysis. A dual parameter multichannel 
pulse height analyzer was utilized for displaying three-
dimensional pulse amplitude distrubitons of enzymatically-
stained cells. The fluorescence of preparations stained 
for leucine aminopeptidase activity was excited at either 
457 nm or at the 351-364 nm doublet, as specified. 
RESULTS 
Comparison of Drug Effects at Whole 
Animal and Organ Level 
The Sl02F and Slow murine adenocarcinomas were 
utilized to compare the efficacy of FT and FU. Both 
single dose and multiple dose regimens were examined. 
The multiple dose treatment protocol consisted 
of ten consecutive daily injections of FT (100 mg/kg) 
or FU (20 mg/kg). An equimolar dose of FU would have 
been 65 mg/kg; however, preliminary studies with multi-
pIe daily injections of FU (40 and 65 mg/kg) indicated 
that the mice were unable to tolerate daily administra-
tion at these dose levels. Therefore, FU was administered 
at a maximally tolerated dose of 20 mg/kg for ten days. 
The growth of Sl02F tumors of mice treated with either 
FU (20 mg/kg) or FT (100 mg/kg) in a multiple dose regi-
men is shown in Figure 4. Day 0 represents the first 
day of treatment. In order to maintain uniformity in 
results between experiments, the first treatment day 
was chosen as the time at which the tumor had grown to 
approximately 200 1l,Q, (+ 50 lJR,). Sl02F tumors begin to 
ulcerate at volumes greater than 800 lJR" thus, measure-
ments of large tumors are meaningless and were not 
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included in the figures. Ten daily injections of FT 
slowed tumor growth for the duration of the treatment 
schedule. Maximally tolerated doses of FU did not have 
a significant antitumor effect. 
Changes in the body weight of the mice were 
monitored during all studies as part of an effort to 
compare drug toxicity to the host. Body weight changes 
as a function of time after the first drug injection are 
shown in Figure 5. At the start of treatment, the mice 
weighed between 23 and 28 g. Control mice injected 
with 0.9% NaCl solution gained about 1 g during the 
course of treatment. With both multiple dose drug 
treatments, the mice lost approximately 3-4 g. The 
body weight of animals which received daily injections 
of FT returned to pretreatmen~ levels between 18 and 24 
days after the initial injection. In contrast, FU-
treated animals remained at 2-3 g below pretreatment 
levels for the duration of the study (approximately 25 
days) . 
A similar study was performed on animals bearing 
the Slow tumor. Groups of tumor-bearing mice received 
either FU {20 mg/kg} or FT (100 mg/kg) for ten consecutive 
days. Drug effects on the growth of the Slow tumor are 
presented in Figure 6. FT exhibited antitumor activity, 
resulting in a slowing of tumor growth for the first 4-8 
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days of treatment, after which the rate of growth approx-
imated that of control tumors. A less pronounced effect 
was observed with a maximally tolerated regimen of FU. 
As shown in Figure 7, the FT and FU treatment protocols 
were more toxic to animals bearing the Slow tumor as 
compared to those bearing the Sl02F tumor (see Figure 5). 
With both drugs, tumor-bearing animals lost between 5 
and 7 g of weight. Although not shown, FT-treated ani-
mals regained their weight to original levels on days 
15-20 after the initial injection, whereas FU-treated 
mice maintained their weight at 3-4 g below control ani-
. mals for the duration of the study. 
Although antitumor agents are usually adminis-
tered clinically in multiple dose regimens, it is ini-
tially essential to study and evaluate biochemical and 
cellular drug-induced perturbations in the simplest sit-
uation following a single dose, before attempting to 
study the more complex conditions following multiple 
dose therapy. Therefore, the effects of large, single 
doses of FT (300 mg/kg) and FU (65 mg/kg) were examined 
in the Sl02F and Slow tumors. Figure 8 illustrates the 
effect of these drug treatments on the growth of the 
Sl02F tumor. Tumor growth was slowed for 3-4 days after 
treatment with either drug. Partial regression was ob-
served 1-3 days after FT or FU treatment in some tumors. 
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Data regarding drug toxicity to animals bearing the 
S102F tumor are shown in Figure 9. Animals which re-
ceived FT (300 mg/kg) lost approximately 1 g within 2 
days after treatment. During the subsequent 3 days, 
their body weight returned to the pretreatment level. 
Mice treated with a single injection of FU (65 mg/kg) 
had an initial weight loss of 2-3 g. This weight loss 
was maintained for 10-12 days after the initial injection. 
The antitumor effect of single, large doses of 
FU and FT was also studied in animals bearing the Slow 
tumor, as shown in Figure 10. In this study, day 0 
represents the first day of tumor measurement rather 
than the day of the first injection. In animals which 
received FT (300 mg/kg) on day 8, tumor growth was dra-
matically slowed for 4-5 days. In some tumors, partial 
regression was observed 1-3 days after treatment. Mice 
treated with FU (65 mg/kg) also showed a decrease in the 
rate of tumor growth for 4-5 days after treatment. With 
both drugs, the rate of tumor growth approximated that 
of controls within 6-8 days after drug injection. How-
ever, even though both drugs exhibited similar antitumor 
activity against the Slow tumor, a dramatic difference 
in host toxicity was observed. Figure 11 indicates that 
animals bearing the Slow tumor, which received a single 
injection of FT (300 mg/kg), lost approximately 2-3 g 
32 
of weight and maintained this weight loss for the dura-
tion of the study. Mice treated with FU (65 mg/kg) 
showed a steady weight loss for 10-12 days after drug 
injection. A maximum weight loss of approximately 8-9 g 
was observed. Animals regained about 50% of their weight 
loss on days 18-20 after the injection. However, des-
pite this large weight loss, none of the FU-treated ani-
mals died. 
Since the marked antitumor effects observed with 
large, single injections of either FT or FU were accom-
panied by a marked weight loss, a study was undertaken 
to evaluate the effect of body weight loss per se on 
the rate of tumor growth. Tumor-bearing mice were 
allowed water ad libitum, while food was withheld until 
the desired weight loss was achieved. This procedure 
was originally designed to induce approximately the same 
degree of weight loss (8-9 g) as was observed in FU-
treated mice. However, mice bearing the Slow tumor were 
not able to tolerate a weight loss of more than 6-7 g. 
Therefore, groups of 8-10 mice were forced to lose 5-6 g 
of weight, which usually occurred in 2-3 days. Tumors 
were measured throughout the duration of the study. The 
effect of this procedure on the growth rate of Slow 
tumors is shown in Figure 12. It is evident that a body 
weight loss of this magnitude did not directly affect 
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tumor growth. Similar results were obtained in animals 
bearing the Sl02F tumor (data not shown) . 
Comparison of Drug Effects at the Cellular Level 
Development of Tumor 
Dispersal Technique 
A procedure to prepare single cell suspensions 
from the solid tumors for FCM analysis was developed. 
A schematic of the TPB dispersal procedure is shown in 
Figure 2 and is discussed in detail in the Methods sec-
tion. Figure l3a shows a hematoxylin and eosin-stained 
histological section of the solid Sl02F tumor. Connec-
. tive tissue and alveolar ducts containing some pyknotic 
cells are clearly visible. A cell suspension of the 
tumor prepared by the TPB procedure is shown in Figure 
l3b. Hematoxylin and eosin-stained cells show a high 
nuclear to cytoplasmic ratio. Although the cells were 
nonviable as determined either by trypan blue or eosin-
y dye uptake, the preparation consisted of single cells 
with minimal nuclear and cytoplasmic debris. Since the 
acriflavin staining is performed on formalin-fixed cells, 
cell viability was unimportant for FCM analysis of DNA 
distributions. 
An uncorrected DNA distribution of acriflavin-
stained TPB-dispersed Sl02F cells is shown in Figure 14. 
As evidenced from this histogram, the level of background 
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fluorescence noise was negligible. The distribution was 
characterized by a small peak at low fluorescence values 
due to normal diploid cells and by a bimodal distribution 
due to near-tetraploid tumor cells. The coefficient of 
variation of the Gl peak was routinely between 4% and 
6%. The TPB technique was also used to disperse Slow 
tumors (data not shown). Although the Slow tumor sus-
pensions appeared to contain more residual debris than 
the Sl02F, DNA histograms were still superior to those 
obtained by a mechanical dispersal procedure (105). 
Computer analysis, of the areas under Gl , G2 + M 
and S phase portions of the histogram is illustrated in 
Figure 15. A Gaussian distribution was used to fit the 
Gl and G2 + M peaks and a second-order polynomial equa-
tion was utilized to fit the S phase portion of the 
histogram (100). Computer analysis of the DNA distri-
bution of several individual Sl02F tumors is shown in 
Table 1. The standard error of the mean of the fraction 
of the tumor cell population in Gl , Sand G2 + M phase 
demonstrates the small inter-tumor variation in these 
data. 
In order to ascertain if the TPB dispersal pro-
cedure was yielding cell suspensions which were repre-
sentative of the in situ tumor, labeling indices were 
determined on histological sections and single cell 
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TABLE 1 
FCM ANALYSIS OF UNPERTURBED S102F TUMORS 
C.v. Fraction of Cells 
Tumor (% ) G1 S G2 + M 
1 4 0.65 0.23 0.12 
2 6 0.67 0.14 0.19 
3 4 0.65 0.25 0.10 
4 5 0.66 0.18 0.16 
5 6 0.65 0.10 0.25 
6 6 0.66 0.14 0.21 
7 5 0.67 0.20 0.12 
8 6 0.65 0.16 0.19 
9 4 0.68 0.18 0.14 
- - - - - - - - - - - - - - - - -
Mean + S.E. 0.66 + 0.01 0.18 +0.02 0.16 + 0.02 
-
computer analysis of DNA distributions of TPB-
dispersed S102F tumors. The values represent the frac-
tion of cells in GI' S, and G2 + M phases. The coef-
ficient of variation (C.V.) of the G1 peak is also 
listed. 
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preparations from the same tumor. As reported previ-
ously (88), the phase durations of the Sl02F tumor in 
hours are as follows: Gl (6.5), S (7.7), G2 (2.5), M 
(0.6) 0 Based on these kinetic parameters, three exper-
imental protocols were utilized to evaluate the random 
selection of cells in various phases of the cell cycle: 
1) 3H- TdR was given to mice bearing Sl02F tumors to 
label those cells in S phase. The mice were then killed 
30 minutes later, and half of the tumor was fixed for 
sectioning, and the remainder was utilized to prepare 
single cell suspensions; ,2) the mice were killed 3 
hours after the single injection of 3H- TdR with the 
labeled cells expected to be in mid to late S, G2 , and 
M phase; and, 3) to obtain labeled Gl cells, mice 
bearing Sl02F tumors were giv~n two injections of 
3H- TdR 6 hours apart and then killed 10 hours after the 
last injection. Although labeled cells will be distri-
buted throughout Gl phase, they will be found in other 
phases of the cell cycle as well. With this protocol, 
the labeling index was expected to be about twice that 
found with a 30 minute pulse. Table 2 shows autoradio-
graphic data for both tissue sections and single cells. 
The labeling indices for the tumor section versus the 
cell suspension correlate highly in each of the the 
three protocols (correlation coefficient, r = + 0.94). 
TABLE 2 
LABELING INDICES IN TUMOR SECTIONS 
AND SINGLE CELL SUSPENSIONS 
Sl02F Labeling Index 
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Description N· Tissue Section Single Cells 
S-Phase 4 0.15 + 0.02 0.17 + 0.03 
- -
Mid to Late S, G2 and 
M-Phase 3 0.15 + 0.01 0.14 + 0.02 
- -
GI-Phase 4 0.31 + 0.01 0.32 + 0.08 
- -
The values represent the mean + S.E. of the 
mean of N samples, where N is the number of tumors 
analyzed per point. 
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These data indicate that gross preferential cell selec-
tion or elimination from a particular phase of the cell 
cycle does not occur with the TPB dispersal procedure. 
FCM Analysis of Perturbed 
Sl02F Tumors 
The effects of FT (100 mg/kg) on the DNA dis-
tribution of Sl02F tumors are presented in Table 3. One 
and 8 hours after drug injection, there was a significant 
increase (p<O.Ol Student's t-test) in the proportion of 
the tumor cell population residing in Gl phase. A cor-
responding decrease was observed in Sand G2 + M phase. 
However, 24 hours after injection, the DNA distributions 
appear to have returned to control values. 
FCM analysis of the DNA content of Sl02F tumors 
perturbed by FT (300 mg/kg) is shown in Table 4. One 
and 8 hours after treatment, there was an increase in the 
percent of cells in S phase with a corresponding decrease 
of the tumor cell population in G2 + M phase. By 12 
hours, the percent of cells with an S phase DNA content 
was 1.5-fold higher than the control value. In con-
trast, at 24 hours after treatment, the fraction of cells 
in S was reduced below the control level, and the major-
ity of the tumor cells appeared to be located in Gl . 
Although the percent of the cells in Gl decreased slight-






























































































































































































































































































































































































































































































































































































































































































































































































the previously high levels again at 36 hours after the 
injection of FT. 
Table 5 represents FCM analysis of the DNA con-
tent of Sl02F tumors perturbed by the systemic adminis-
tration of FU (65 mg/kg). The percent of the tumor cell 
population in G2 + M phase increased from 17% to 22% 
within 1 hour after drug injection. Eight hours after 
treatment, there was marked increase in the percent of 
cells in S phase and a significant decrease in the tumor 
cell population residing in G2 + M phase. This was fol-
lowed 16 hours later (the duration of approximately one 
cell cycle) by an increase in cells in Gl . The percent 
of the tumor cell population in Gl phase continued to 
be elevated at 36 hours after treatment, whereas the 
percent of cells in Sand G2 + M phase was drastically 
reduced. 
Autoradiography was utilized to confirm selected 
portions of the data obtained by FCM analysis of per-
turbed Sl02F tumors. Specifically, changes in labeling 
indices at various times after drug treatment were 
correlated with changes in the fraction of cells in S 
phase as determined by FCM analysis. SlC2F tumor-
bearing animals were treated with either FU (65 mg/kg) 
or FT (300 mg/kg). 3H- TdR was administered at various 







































































































































































































































































































































































































































































































































































30 minutes later. Intervals were chosen such that the 
maximum changes in cells in S phase, as determined by 
FCM analysis, would also be evaluated by autoradio-
graphic techniques. Thus, tumors prepared 8 hours and 
36 hours after FU treatment, in which the percent of 
cells in S phase was 28 and 8, respectively, were uti-
lized for autoradiography. In addition, autoradio-
graphic analysis was done on FT (300 mg/kg)-treated 
tumors 12, 24, and 36 hours after injection in which the 
fraction of the tumor cell population in S phase was 26, 
7, and 8%, respectively. These data are presented in 
Table 6. Both labeled and degenerate (pkynotic and 
karyorrhectic) cells were scored. Eight hours after 
FU treatment, the degenerate index (D.I.) was not 
different than control. There was a significant in-
crease (p<O.Ol, Student's t-test) at 36 hours after FU. 
In contrast, the D.I. increased at 12 and 24 hours after 
FT treatment and returned to control levels at 36 hours 
after the initial injection. The labeling indices of 
Sl02F tissue sections were observed to change in the 
same direction as did the fraction of the cells in S 
phase, as determined by FCM (Tables 4 and 5). 
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TABLE 6 
AUTORADIOGRAPHY: Sl02F TISSUE SECTIONS 
Treatment: Labeling Degenerate 
Hr Post Injectiona N Index Index 
Control 4 14.4 + 1.7 0.4 + 0.1 
- -
FU: 8 hr 4. 20.6 + 1.5 0.4 + 0.1 
- -
FU: 36 hr 4 0.9 + 0.3b 1.0 + o .lb 
- -
FT: 12 hr 5 20.6 + 1.5 0.8 + 0.3 
- -
FT: 24 hr 5 3.3 + l.lb 1.0 + 0.1 
- -
FT: 36 hr 3 0.5 + 0.2b 0.4 + 0.1 
- -
Values represent the mean + S.E. of the mean, 
where N is the number of samples per group. 
a FU : 65 mg/kg, i.p. 
FT: 300 mg/kg, i.p. 
bp<O.Ol (Student's t-test) vs. control. 
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Drug Effects at the Molecular Level: 
Tumor and Small Intestine 
The incorporation of deoxyuridine into DNA re-
lates, in part, to the activity of thymidylate synthe-
tase and, therefore, was utilized to investigate bio-
chemical lesions induced by FT and FU. Tumor-bearing 
mice received either FT, FU, or an equivalent volume of 
0.9% NaCl solution. At various intervals thereafter, 
they were injected with 3H- UdR . Thirty minutes later, 
the mice were killed and the extent of incorporation of 
the labeled precursor into DNA was measured. 
The effect of equimolar doses of FT and FU on 
3H- UdR incorporation into DNA of the Sl02F tumor is 
shown in Figure 16. Within 1 hour after administration 
of FT, the 3H- UdR incorporation was approximately 
mately 25-30% of that observed in the tumors from con-
trol animals. 3H- UdR incorporation had increased sig-
nificantly at 12 hours after injection, and at 24 hours 
after treatment, it was not significantly different 
f 1 d d 3 Ud . . t rom contro s. FU epresse H- R 1ncorporat1on 0 
10% of control values for at least 24 hours after drug 
injection. By 48 hours, it was again elevated signifi-
cantly and approximated that of controls 72 hours after 
FU injection. 
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Drug-induced changes in the extent of 3H- UdR 
incorporation into DNA of the small intestine of mice 
bearing the Sl02F tumor after systemic administration of 
equimolar doses of FU and FT are illustrated in Figure 17. 
Although both drugs depressed incorporation to approxi-
mately 10% of the control level at 1 hour after injection, 
the intestine of animals treated with FT recovered at a 
faster rate (complete recovery observed in 24 hours) than 
did that from FU-treated mice. In each case, however, 
the rate of recovery proceeded more rapidly in the small 
intestine than in the Sl02F tumor (Figure 16). 
An analogous study was completed in animals 
bearing the Slow tumor. These results are shown in 
Figure 18. FT (100 mg/kg) depressed 3H- UdR incorpora-
tion to approximately one-third of control levels for 
at least 12 hours after treatment, and by 24 hours it 
had exceeded control levels. However, an equimolar dose 
of FU depressed incorporation to approximately 15% of 
control levels for 48 hours after drug injection, and 
even at 72 hours after treatment, 3H- UdR incorporation 
was still only about one-third of the control level. As 
shown in Figure 19, incorporation of 3H- UdR into the DNA 
of the small intestine of animals bearing the Slow tumor 
was inhibited by about 90% at 1 hour after the injection 
of either drug. This low level of incorporation was 
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maintained for 24 hours after FU treatment, whereas the 
intestine of FT-treated mice returned to control levels 
within the same period. At 72 hours after FU treatment, 
3H- UdR incorporation in the small intestine of mice bear-
ing the Slow tumor appeared to approximate that of con-
troIs. 3 In contrast, H-UdR incorporation in the intestine 
of animals bearing Sl02F tumors returned to control levels 
48 hours after FU treatment (Figure 17). The data in 
Figure 20 compare the effect of FT (300 mg/kg) and FU 
(65 mg/kg) on 3H- UdR incorporation into DNA of the Sl02F 
3 d . .. d f tumor. H-U R 1ncorporat1on 1S presente as percent 0 
control values. At 1 hour both drugs depressed 3H- UdR 
incorporation to 10% of control levels. The rate of 
recovery of the tumor followed a similar pattern with 
both drugs. 
Incorporation of 3H- UdR into DNA is sometimes 
used as an indication of the rate of DNA synthesis (4, 
107). However, data obtained by FCM analysis of perturbed 
Sl02F tumors did not correlate with the studies of 3H- UdR 
incorporation into DNA. For example, 3H- UdR incorpora-
tion into DNA of the Sl02F tumor after FU treatment was 
depressed to 10% of control levels for more than 36 hours 
(Figure 16). But FCM analysis of Sl02F tumors perturbed 
by the systemic administration of FU indicated that cells 
were moving in and out of S phase during that 36 hour 
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period (Table 5). 32 Thus Na 2H P04 incorporation into DNA 
was utilized as an independent measure of overall DNA 
synthesis. Sl02F tumor-bearing animals were treated 
with FU (65 mg/kg). At I, 8, 24, or 36 hours after drug 
d .. . h' .. d' h 32 d a mlnlstratlon, t e mlce were In]ecte Wlt P an 
killed 30 minutes thereafter. The data in Table 7 show 
that the incorporation of 32p into tumor DNA was depressed 
to 50% of control levels 1 hour after drug injection. 
However, incorporation was not significantly different 
(p<O.Ol, Student's t-test) from control levels 8 hours 
after injection. This is in contrast to the results ob-
tained with respect to 3H-UdR incorporation, which was 
depressed for more than 48 hours after FU treatment 
(Figure 16). At 24 and 36 hours after FU treatment, 32p 
incorporation was again depressed to 50% of control 
values. 
Intestinal Epithelial Cells: Isolation, 
Dispersal, and Separation 
Techniques were developed to prepare single cell 
suspensions of intestinal crypt and villus cells for FCM 
analysis. A phase contrast photomicrograph of an un-
stained epithelial cell suspension is shown in Figure 21. 
Crypt cells, which tend to be smaller than villus cells, 
displayed a high nuclear to cytoplasmic ratio and lacked 
TABLE 7 
32p INCORPORATION INTO DNA OF S102F TUMOR 
Time Post cpm/lJMole 
Treatmenta N Deoxyribose 
Control 11 576 + 64 
-
1 Hour 7 291 + 3lb 
-
8 Hour 9 429 + 90 
-
24 Hour .8 198 + 46b 
-
36 Hour 7 252 + 44b 
-
Each value represents the mean + S.E. of the 
mean of 7-11 samples. 
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a FU (65 mg/kg) inject~d i.p. at 0 hour. 
bSignificantly different than control, p<O.Ol 
(Student's t-test). 
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visible microvilli. Villus cells were observed to have 
distinct brush borders and contained more cytoplasm 
than did crypt cells. 
The dispersal procedure was based on incubation 
of the small intestine in EDTA and dithiothreitol (94). 
EDTA was used to dissociate the cells and dithiothreitol 
acted as a mucolytic agent. Cells were isolated in a 
sequential manner with upper villus cells being removed 
early during the incubation period and crypt cells at 
later time periods. It was necessary to determine the 
optimal time interval for maximum crypt cell removal. 
Mice received a 30 minute pulse of 3H- TdR prior to 
sacrifice to label the proliferating crypts. Cells were 
then isolated at 10 minute intervals during the incuba-
tion period and radioactivity ~ue to incorporation of 
the labeled precursor was determined. The results are 
shown in Table 8. These data demonstrated that the 20-
100 minute incubation period yielded cells which had in-
co~porated 3H- TdR and, thus, were proliferating. Since 
villus cells are not cycling, the fraction of cells ob-
tained during this incubation interval was utilized as 
an enriched crypt preparation. 
Figure 22a illustrates an enzymatically-stained 
epithelial cell suspension, as viewed under the light 
microscope. A small, round crypt cell is located 
TABLE 8 
INCORPORATION OF 3H- TdR INTO DNA OF 
INTESTINAL EPITHELIAL CELLS 












3H- TdR was administered to mice 30 minutes 
prior to cell isolation. Cells were collected dur-




between several hemi-ellipsoid villus cells in the center 
of the field. Figure 22b depicts the same field of 
cells, but with fluorescent illumination. The villus 
cells fluoresced brightly, whereas the crypt cell, with 
low enzyme activity, had minimal fluorescence. These 
photomicrographs demonstrate that the leucine aminopep-
tidase reaction was specific for villus cells. 
Crypt and villus cell suspensions, incubated 
with the leucine aminopeptidase substrate, were analyzed 
by the FCM equipped with a cell sorter. The resulting 
histogram was displayed in three dimensions, with enzyme 
fluorescence viewed as a function of low-angle (0-7°) 
forward scatter (related to cell size) and cell number. 
Linear amplification of fluorescence and low-angle 
forward scatter of a mixed epithelial cell preparation 
is shown in Figure 23 (a and b). Two distinct popula-
tions are clearly visible. Logarithmic amplification 
of enzyme fluorescence and small-angle scatter of the 
same cell suspension is shown in Figure 24 (a and b). 
This histogram displayed four distinct populations. 
Electronic sorting was done on cells comprising the var-
ious portions of the histogram. Microscopic examination 
of sorted cells indicated that the crypts were localized 
in two areas: the small peak with low fluorescence and 
high forward angle scatter and the peak which exhibited 
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relatively high enzyme fluorescence but low forward angle 
scatter values. The villus cells were located under the 
largest peak in the histogram, with high enzyme fluores-
cence and forward angle scatter values. The small peak 
with low fluorescence and forward angle scatter consisted 
of debris and cell fragments. Photomicrographs of the 
sorted crypt and villus populations are shown in Figure 25 
(a and b). The amount of villus contamination based on 
morphological criteria in the crypt sort was less than 
0.1%. No crypt cells were found in the sorted villus 
population. 
To ascertain that the cells sorted as crypts 
were, indeed, the proliferating cells of the small in-
testine, sorting was done on epithelial cell prepara-
tions, obtained from mice who had received a 30 minute 
pulse of 3H- TdR prior to cell isolation. Autoradiog-
raphy was performed on both the sorted crypt and sorted 
villus populations. The labeling index on the sorted 
crypts varied from 10-12%. Labeled cells were not ob-
served in the sorted villus fraction. 
The histograms shown in Figure 24 (a and b) were 
obtained under less than optimal enzyme conditions. Due 
to insufficient amounts of NSA coupler in the original 
incubation medium, enzyme product produced within the 
villus cells diffused out into the crypts. Although the 
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relative position of the crypts along the y-axis of the 
histogram in Figure 24 indicated that they were smaller 
than the villus cells, their location along the x-axis 
indicated that they had considerable enzyme fluorescence. 
By increasing the amount of NSA in the incubation mix-
ture, according to the procedure described in the Methods 
section, the histograms shown in Figure 26 (a .and b) were 
obtained. As evidenced from microscopic examination, the 
crypts were localized along the y-axis. Villus cells, 
which were larger and more fluorescent than the crypts, 
were seen along the x-axis with high forward angle scat-
ter values. When alkaline phosphatase, instead of leucine 
aminopeptidase, was utilized as the fluorescent enzyme 
marker, histograms similar to those seen in Figure 25 
were obtained. 
Restaining of the sorted crypt and villus pop-
ulations with a DNA-specific dye was attempted. The 
emission spectra of the enzyme product-NSA complex 
ranges from 480-615 nm (96). The complex can be excited 
with wavelengths from 340-460 nm. Since the enzyme prod-
uct remained in the cells indefinitely, a DNA-specific 
dye with a different emission maximum than the enzyme 
complex was needed to obtain accurate FeM analysis of 
DNA distributions of the sorted cells. Hoechst 33258 
was chosen for this purpose. Hoechst 33258 is maximally 
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excited at 350 nm and has a maximum emission at 450 nm. 
With appropriate filters, e.g., 466 band pass, in the 
photomultipliers of the FCM, it was possible to block 
out the enzyme fluorescence and detect only the DNA-
specific Hoechst fluorescence. Although many attempts 
were made to analyze sorted samples stained with Hoechst 
33258, the DNA distributions were difficult to evaluate. 
The sorted villus cells yielded DNA distributions with 
a definite Gl peak and a small peak probably due to cell 
clumps. However, the sorted crypts DNA distribution did 
not show either an S phase or G2 + M phase, as would be 
expected from a proliferating population. 3H- TdR auto-
radiographic studies were done to verify that the pro-
liferating intestinal epithelial cells were removed from 
the small intestine during the isolation procedure. 
These data indicated that: 1) very few labeled cells 
remained in the intestine after cell isolation, and, 2) 
the sorted crypt population had a 10-12% labeling index. 
Thus, although S phase cells were present as determined 
by autoradiography, they were not detected by FCM analy-
sis. 
Several studies were also carried out to de-
termine if it would be possible to simultaneously eval-
uate epithelial cells stained for LAP and for DNA. Such 
a technique would eliminate the lengthy sorting 
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procedure and make it possible to obtain a DNA distri-
bution of only the proliferating crypt cells. Since 
Hoechst 33258 is maximally excited in the u.v. region, 
it was verified that u.v. excitation of LAP-stained 
cells yielded similar histograms as those obtained after 
excitation at 457 nm. For dual staining, cells were 
first incubated with the LAP substrate and then stained 
with Hoechst 33258. Microscopic examination of dually-
stained cells showed a fluorescent blue nucleus and 
yellow cytoplasm. Through a combination of filters 
placed in the photomultiplier tubes of the FCM, it was 
possible to distinguish the Hoechst 33258 fluorescence 
of the proliferating crypts from the Hoechst plus enzyme 
fluorescence of the villus cells. However, the problem 
of obtaining an adequate DNA distribution of the crypts 
remained. Thus, even though the crypt and villus pop-
ulations could be separated, further work was needed to 
obtain DNA distributions of the sorted samples. Several 
experiments are suggested and discussed in the following 
section. 
DISCUSSION 
FU and FT have antitumor activity against the 
Sl02F and Slow murine mammary tumors. Both drugs are 
most effective when administered as a single, large 
dose. Multiple injections of FT given to animals 
bearing the Sl02F tumor have somewhat greater anti-
tumor effects than do maximally tolerated doses of FU 
(Figure 4). In animals bearing the Slow tumor, multi-
ple injections of either drug have similar antitumor 
'activity (Figure 6). Although FT has been reported by 
some investigators to have twice the therapeutic index 
of FU (66, 67), other reports have indicated that FT is 
not more effective than or even as effective as FU 
(76, 101, 102). Van Putten et ale (103) showed that 
FU, in a single dose, was two- to three-fold more 
potent than FT against leukemic stem cells. However, 
with multiple dose treatment, FU was much more potent 
than FT. Results presented in this study demonstrate 
that FU is two to three times more potent than FT on 
a molar basis. Single or multiple dose treatments do 
not seem to affect this ratio. However, similar anti-
tumor effects can be achieved with larger doses of FT. 
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The advantage of FT over FU lies in the decreased host 
toxicity at a dose which results in similar antitumor 
activity. In all cases, animals which received FT re-
covered from drug-induced toxicity at a faster rate 
than did FU-treated mice (Figures 5, 7, 9, 11). In 
fact, mice bearing the Slow tumor did not completely 
recover from the toxic effects of FU given either as a 
single injection or in a multiple injection regimen. 
Moreover, host toxicity persisted beyond the period of 
effective antitumor activity. Based on these results, 
it may be concluded that FT is less toxic to the host 
than FU when the two drugs are administered at equally 
effective tumor doses (Figures 8 and 9) . 
The decreased toxicity of FT might be due to a 
variety of factors. Van Putten et ale and others (103) 
reported that FU was two to three times more potent 
than FT in killing hematopoietic stem cells. Moderate 
leukopenia and thrombocytopenia were observed following 
administration of FT (133 mg/kg) and FU (23 mg/kg) for 
six days by Hrsak et ale (69). However, the decrease 
in the total number of colony forming units (CFUS) fol-
lowing FT administration was less than that observed 
after treatment with FU. In addition, subsequent re-
covery of CFUS in the marrow was more rapid after FT. 
Clinical trials have also indicated that FT is less 
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myelosuppressive than conventional FU therapy (65, 68, 
71-75, 104). Variances in the physiologic disposition 
and metabolism of FT may also contribute to its de-
creased toxicity compared to FU (79). 
Another major part of this study was to compare 
the cell cycle perturbations induced by FT and FU. FCM 
analysis of DNA distributions of cells in suspension is 
a rapid method by which cell cycle perturbations can be 
examined. However, FCM analysis of the DNA content of 
solid tumors necessitates tumor dispersal into single 
cell suspensions. TPB, q potassium-complexing agent, 
was utilized as an agent to aid dispersal of solid mur-
ine tumors into single cells. TPB-dispersed Sl02F 
tumor cells yield superior DNA distributions than those 
obtained by a previously repo~ted mechanical dispersal 
technique (105). 
The TPB dispersal technique was utilized to 
compare the in vivo cell cycle effects of FT and FU on 
the Sl02F tumor. FT (100 mg/kg) induced small but 
statistically significant increases in the fraction of 
cells in Gl phase up to 8 hours after injection (Table 
3). At 24 hours after treatment, the cell cycle age 
distributions appeared to have returned to control 
values. Since dramatic antitumor effects were not ob-
served with a single injection of FT (lOa mg/kg) 
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(Figure 4), it is perhaps not surprising that marked 
cell cycle perturbations were not observed. FT admin-
istered at a dose of 300 mg/kg exerted more dramatic 
effects on tumor growth (Figure 8) and on the age 
distribution of Sl02F tumor cells (Table 4). For ex-
ample, a one and one-half-fold increase in the percent 
of cells in S phase was noted at 12 hours after injec-
tion of the drug. This possibly may be indicative of 
a drug-induced decrease in the rate of transit of cells 
through this phase of the proliferating cycle. The de-
creased percentage of cells in G2 + M at this time is 
consistent with this possibility. At 24 hours after 
,treatment, an increase in the percent of cells in Gl and 
a corresponding decrease in the percent of cells in S 
phase were observed. These results suggest that a syn-
chronized cohort of cells arrested in early S phase at 
12 hours had progressed through S, G2 , and M (total dur-
ation in unperturbed tumors, 12 hours) and into Gl • The 
fact that the phase distribution at 36 hours was almost 
identical to that observed at 24 hours suggests that the 
synchronization induced by FT treatment was maintained, 
at least, for a duration approximately equivalent to 
two cell cycles. Since the FCM analysis does not pro-
vide any information about dead or dying cells, or about 
changes in cell cycle phase durations, i.e., transit 
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times, a more detailed understanding of the mechanism 
of FT-induced cell cycle perturbations will be attained 
only after evaluation by other experimental techniques, 
such as percent labeled mitoses analysis and autoradi-
ography_ Limited autoradiographic studies were per-
formed at selected intervals after drug treatment to 
verify that changes in the S phase populations did 
represent actual cell cycle perturbations and were not 
merely artifacts of the FCM analysis. For example, FCM 
analysis indicated that the percent of cells in S phase 
at 24 and 36 hours after ,treatment with FT (300 mg/kg) 
was 7 and 8%, respectively (Table 4) _ This may be com-
pared to a value of 17% in control tumors. Autoradio-
graphy also indicated a significant decrease in the 
labeling index of Sl02F tissue sections prepared at 
those same time points (Table 6). These data indicate 
that FCM analysis accurately reflected in vivo cell 
cycle perturbations. 
The effects of FU (65 mg/kg) on Sl02F tumor DNA 
distributions were also examined. FCM analysis revealed 
that there was a marked increase in the fraction of the 
tumor cell population in S phase between 2 and 16 hours 
after drug injection (Table 5). Studies at later inter-
vals indicated that cells which had accumulated in S 
phase were released shortly thereafter~ Thus, the 
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increased percent of cells in Gl phase at 28 hours might 
be interpreted as having resulted from the progression 
of a cohort of cells released from an S phase block 
sometime between 14 and 24 hours. However, the fact 
that the proportion of cells in Gl phase remained ele-
vated 36 hours after treatment might also suggest the 
possibility of a Gl/S block. These data are consistent 
with the hypothesis that FU initially induced an accumu-
lation of cells in S phase and then at 24-28 hours after 
drug injection prevented cells from making the Gl to S 
phase transition. A Gl/S block following treatment with 
FU was also reported by Kovacs et ale (4) in studies on 
the rat hepatoma 3924A. 
FU, after conversion to FUdRP, is believed to 
exert its antitumor and toxic effects through inhibition 
of thymidylate synthetase (27, 28). Since FT is be-
lieved to be a depot form of FU, it was of interest to 
compare the effects of equimolar doses of FT and FU on 
thymidylate synthetase activity in the Sl02F and Slow 
tumors and in the small intestine. In both tumors, 
3H-UdR incorporation was depressed to one-third of 
control levels within 24 hours. 3H- UdR incorporation 
was depressed by 90% at 1 hour after FU (65 mg/kg) and 
only began to recover 48-72 hours later. Therefore, in 
both tumors, FU was a more potent inhibitor of thymidy-
late synthetase than an equimolar dose of FT. Similar 
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results were obtained in the small intestine of both 
SlQ2F and Slow tumor-bearing animals. These data are 
in agreement with those of Cohen (106), who reported 
less inhibition and faster recovery of 3H- UdR incorpor-
ation into DNA of rat small intestine after FT than FU, 
in equimolar doses. In previously reported studies 
(106), neither FT or FU inhibited thymidine incorpora-
tion into DNA, another indication that both drugs acted 
on thymidylate synthetase. 
As discussed above, FCM analysis of FT and FU-
treated Sl02F tumors indicated that cells were moving 
in and out of S phase during the 24-36 hour period 
studied. 3 However, H-UdR incorporation into DNA of the 
Sl02F tumor was depressed for at least 24 hours after 
both FU (65 mg/kg) and FT (300 mg/kg). Therefore, in 
order to resolve this apparent contradiction, the incor-
poration of Na
2
H32po4 into tumor cell DNA was utilized 
as an index of overall DNA synthesis. The results ob-
tained from studies of 32p incorporation (Table 7) in 
mice treated with FU (65 mg/kg) correlated with FCM anal-
ysis of tumor DNA distributions (Table 5). It was 
assumed that such a correlation would also be found for 
FT-treated tumors. These data suggest that results ob-
tained ~rom in vivo 3H- UdR incorporation studies in 
animals treated with fluorinated pyrimidines provide an 
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indication of drug effects on thymidylate synthetase 
activity but do not accurately reflect ongoing DNA syn-
thesis. Therefore, previously reported studies in which 
3H- UdR incorporation was utilized as an index of the 
rate of DNA synthesis (4, 107), should be re-evaluated 
in the light of this finding. Thus, even in the pres-
ence of an almost complete inhibition of thymidylate 
synthetase, tumor cells may utilize salvage pathways to 
generate thymidine triphosphate (108). The data ob-
tained in the studies with 32p indicate that mouse mam-
mary tumor cells can use these pathways to maintain 
moderate rates of DNA synthesis after treatment with 
fluorinated pyrimidines. 
In order to utilize FCM for analysis of the 
age distribution of the proliferating crypts, it is 
necessary to obtain a pure crypt cell suspension. 
Several procedures have been described for obtaining 
"crypt" preparations from the small intestine of the 
rat (94, 109,110). In this study, modifications of 
published procedures were utilized to obtain crypt 
epithelial cells from the small intestine of mice. Al-
though most of these techniques did yield enriched crypt 
cell populations, the final preparations were always 
contaminated by variable amounts of villus epithelium. 
In addition, cell clumping was a common problem in all 
the preparations. 
65 
The protocol described by Weiser (94) for iso-
lating epithelial cells was modified and optimized for 
the mouse small intestine. The modified technique 
yielded a suspension of intact epithelial cells. Ex-
periments in which 3H- TdR was injected prior to crypt 
isolation indicated a six-fold increase in the specific 
activity of the crypt preparation as compared to that 
in the initial villus fraction (Table 8). 
Cells obtained by this technique were primarily 
single, although some clumping did occur. Microscopic 
examination indicated the clumps were due to fragments 
of crypt and villus epithelia which had not been sep-
arated and to contaminating mucus which tended to 
aggregate the single cells. Undispersed epithelial 
fragments were separated by passage of the suspension 
through needles of successively smaller diameter and 
subsequent filtration through 37 ~m nylon mesh. Mucus 
originating from the intestinal goblet cells and the 
ground substance of the submucosa (Ill) posed a more 
difficult problem. Several mucolytic agents, such as 
N-acetyl-l-cysteine and dithiothreitol were utilized with 
moderate success. The most effective mucolytic proce-
dure involved incubation of the isolated epithelial 
cells in a solution containing ascorbic acid, hydrogen 
peroxide, and copper sulfate. This combination was 
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originally described for use in bronchial inhalers (112) 
and was reported to irreversibly cleave mucoprotein 
bonds (95). It did not appear to affect epithelial 
cell viability, as measured by trypan blue exclusion, 
or cell morphology. 
It is known that crypt and villus cells differ 
both morphologically and biochemically. Villus cells 
are highly specialized for digestive and absorptive 
functions, whereas the crypt cells are proliferating and 
nondifferentiated. It has been shown with both tissue 
sections and fractionated epithelial cell homogenates 
that specific enzymes are localized primarily in villus 
epithlia (108, 113-115). Nonspecific esterases, alka-
line phosphatase, lactate dehydrogenase, leucine amino-
peptidase, and a variety of other enzymes are found to 
increase in activity as the crypt cell migrates onto the 
villus. Several of these enzymes, including leucine 
aminopeptidase and alkaline phosphatase, are associated 
with microvilli (108, 113, 116-119). Crypt cells con-
tain very few microvilli, which only begin to appear 
in great numbers as these cells migrate onto the villus. 
Fluorescent enzyme histochemical reactions were 
utilized in combination with the FCM to separate the 
crypt and villus populations. Leucine aminopeptidase 
(LAP) acts to split off the terminal amino acids from 
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proteins and polypeptides (120). It reacts most rapidly 
with leucine-containing compounds. Since this enzyme 
exhibits high activity in epithelial cell brush borders 
(e.g., microvilli), it was reasoned that a fluorescent 
enzyme product should be preferentially localized in 
villus cells. L-leucyl-4-methoxy-8-napthylamide is 
hydrolyzed to LAP to yield a free napthylamine (96). 
This product exhibits a blue fluorescence but is ex-
tremely soluble and will easily diffuse out of the 
area of enzyme activity. Therefore, a coupling agent, 
NSA, was utilized to precipitate the reaction product 
"in situ. NSA is nonfluorescent. However I when NSA is 
coupled to napthylamines by a Schiff-base reaction, the 
fluorescence of the napthylamine shifts to longer wave-
lengths, and the resulting complex has a yellow-orange 
fluorescence. 
FCM analysis and subsequent cell sorting of 
enzymatically-stained cells indicated that crypt and 
villus cells could be separated on the basis of LAP 
activity (Figures 23-26). Autoradiographic studies on 
unsorted and sorted epithelial cells indicated that all 
of the radioactive label was associated with crypt cells. 
Attempts to restain the sorted crypt and villus 
populations with a DNA-specific dye met with minimal 
success. The NSA-LAP product complex remained inside 
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the cell and could not be removed either by alkali 
treatment or by solvent extraction. Thus, restaining 
the sorted LAP-stained cells with a DNA-specific dye 
necessitated the use of a dye with a different emission 
spectrum than that of the enzyme product complex. 
Spectral analysis of the NSA-enzyme product indicated 
that the complex could be excited between 340 and 460 nm 
and that the emission spectrum was between 480 and 
615 nm, with peaks at 530 and 595 nm (data not shown). 
Therefore, a DNA-specific dye with minimal green-red 
fluorescence was needed. Spectral analysis of several 
of the commonly availab1e stains (chromomycin, propidium 
iodide, etc.) indicated that Hoechst 33258 was one of 
the few DNA stains which fulfilled this criterion. 
Hoechst 33258 is maximally excited in the ultraviolet 
region and has a maximum emission wavelength of 460 nm. 
With appropriate filters in the photomultipliers of the 
FCM, it was possible to block out the enzyme product 
fluorescence and detect only the DNA-specific Hoechst 
fluorescence. Although an acceptable DNA distribution 
of the sorted villus cells was obtained, Hoechst 33258-
stained crypts yielded uninterpretable DNA distributions. 
The Sand G2 + M phases were not discernible, whereas a 
peak which might have represented Gl cells was unusually 
broad. Part of the problem encountered in restaining 
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the sorted cells may have resulted from the choice of 
the DNA-specific dye, Hoechst 33258. In order to ob-
tain nuclear fluorescence with minimal cytoplasmic 
fluorescence, the concentration of the dye was fifty-
fold lower than that used in previously reported proto-
cols with Chinese hamster ovary cells (98). Although 
only the nucleus appeared to fluoresce under these 
conditions, it is possible that the fluorescence of the 
crypt nucleus was not stoichiometrically related to DNA. 
It has been shown with particular stains that the 
characteristics of DNA-staining may vary from one cell 
type to another (121-124). The fact that it was neces-
sary to drastically reduce the Hoechst 33258 concentra-
tion might also indicate that the intestinal crypt cells 
stain differently than other cell types. 
Additional studies are needed to resolve the 
problems observed in obtaining a DNA distribution of the 
intestinal crypt cells. For example, individual measure-
ments of the amount of DNA in Hoechst 33258-stained cells 
should be correlated wtih their location in the DNA dis-
tribution obtained by FCM. Such a study would confirm 
the possibility that crypt nuclear fluorescence was not 
stoichiometrically related to DNA. If this were the 
case, further modifications of the DNA-staining protocol 
could then be made. The use of NSA as a coupling 
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reagent in the enzyme reaction may also contribute to 
the problem of obtaining interpretable crypt DNA dis-
tributions. Aromatic aldehydes react with proteins 
containing either aromatic amines or primary aliphatic 
amino groups, e.g., y- or E-amino groups. NSA, like 
formaldehyde and ethanol, is bound to cell proteins, 
producing a weak, greenish background fluorescence. 
The possibility exists that NSA may bind to the nuclear 
histones involved in maintaining DNA structure and, 
hence, affect the stoichiometry of a DNA-specific dye. 
Since an adequate DNA distribution of Hoechst-
stained cells was not obtained, the effects of FU and 
FT on the age distribution of the proliferating crypts 
were not evaluated. Although further development of the 
DNA staining procedure is needed, the separation of 
enzymatically-stained crypt and villus cells by the FCM 
was successful. 
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1 FU ... .. FUR .. • FUMP I 1 TMP ; FUdR .. FdUMP .. 
dUMP 
Figure 1. Anabolism of S-Fluorouracil. S-Fluorouracil 
(FU) , S-fluoro-2'-deoxyuridine (FUdR), S-fluoro-2'-
deoxyuridine S'-monophosphate (FdUMP), S-fluoro-uridine 
5'-monophosphate (FUMP), deoxyuridylate (dUMP), thymi-
dylate (TMP), S-fluorouridine (FUR), S-fluorouridine 






















































































































































































































































































































Centrifuge SOO xg 
for 5 minutes 
, 
Discard 
Supernatant Resuspend cell pellet in PBS. Let 











Resuspend cell pellet in 4 N lIel. 




Resuspend in distilled water. 





Supernatant Resuspend cell pellet in acriflavin. 
Cap and let stand at room temperature 









Resuspend cell pellet in acid alcohol. 











Supernatant Resuspend pellet in distilled water. 
WrAp tube in aluminum foil. Store'at 
"·C. 
Figure 3. Acriflavin-Feulgen Staining Protocol 
Figure 4. Inhibition of growth of Sl02F tumors by 
multiple injections of FT and FU. The lines in this 
figure and all following figures were fitted by eye. 
Each data point represents the mean of 8-12 tumors. 
88 
The vertical bars show one S.E. of the mean. For clar-
ity, only half of the error bar is shown. Drug treat-
ment was initiated on Day 0 and continued for 9 days 
thereafter. 
• • 
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Figure 5. Host toxicity of multiple injections of FT 
and FU in mice bearing Sl02F tumors. Each data point 
represents the mean body weight change of mice bearing 
the Sl02F tumor. These are the same mice whose tumor 
growth is shown in Figure 4. The vertical bars show 
the S.E. of the mean of 8-10 mice. Drug injections 
began on day 0 when the tumor volume was approximately 
200 ~t and continued for 9 days therafter. The pre-
treatment weight of the mice was between 22 and 28 g. 
• • 
.... _ .... 
Control 
FT (100 mg/kg) 
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Figure 6. Inhibition of growth of Slow tumors by 
multiple injections of FT and FU. Each data point 
represents the mean of 8-12 tumors. The vertical bars 
show one S.E. of the mean. Drug treatment was initiated 
on Day 0 and continued for 9 days thereafter. 
•• Control 
... -..... FT (100 mg/kg) 
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Figure 7. Host toxicity of multiple injections of FT 
and FU in mice bearing Slow tumors. Each data point 
represents the mean body weight change of 8-10 mice. 
These are the same mice whose tumor growth shown in 
Figure ,6. The vertical bars show the S.E. of the mean. 
Drug injections began on Day 0 when the tumor volume 
was approximately 200 ~£ and continued for 9 days there-
after. The pretreatment weight of the mice was between 
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Figure 8. Inhibition of the growth of Sl02F tumors by 
a single injection of FT or FU. Each data point repre-
sents the mean tumor volume of 9-10 tumors. The ver-
tical bars show the S.E. of the mean. A single'injec-
tion of either drug was given on Day O. 
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Figure 9. Host toxicity of a single injection of FT or 
FU in mice bearing the Sl02F tumor. Each data point 
represents the mean body weight change of 9-10 mice 
bearing the Sl02F tumor. These are the same mice whose 
tumor growth is shown in Figure 8. The vertical bars 
show the S.E. of the mean. Drugs were administered on 
Day 0 when the tumor volume was approximately 200 11£. 
The pretreatment weight of the mice was between 22 and 
28 g. 
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Figure 10. Inhibition of the growth of the Slow tumor 
by a single injection of FT or FU. Each data point 
represents the mean tumor volume. The vertical bars 
show the S.E. of the mean of 10-15 tumors. Day 0 rep-
resents the first day of tumor measurements. FT was 




•. - .... 
Control 
FT (300 mg/kg) 
FU (65 mg/kg) 
450 
:t. 




















n: .. ~ 
.*~/ 
/-\A' 7 ~£ 
101 
o 4 8 12 16 20 24 28 
NO. or D/\YS 
102 
Figure 11. Host toxicity of a single injection of FT 
or FU in mice bearing the Slow tumor. Each data point 
is the mean body weight change of 10-15 mice. These 
are the same mice whose tumor growth is shown in 
Figure 10. The vertical bars show the S.E. of the mean. 
Day 0 represents the day of drug administration. The 
pretreatment weight of the mice was between 22 and 28 g. 
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Figure 12. Effect of body weight loss on the growth of 
the Slow tumor. Each data point represents the mean 
volume of 9-12 tumors. Food was withheld on Day 0 and 
for 2-3 days thereafter. The mean + S.E. weight loss 
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Figure 13. (a) Histological section of the Sl02F 
tumor. Stained with hematoxylin and 
eosin. 
(b) Single cell suspension of the Sl02F 
tumor prepared with TPB. Stained with 




Figure 14. An uncorrected DNA distribution of an 
acriflavin-stained Sl02F single cell suspension pre-
pared with TPB. Note the low level of background 
fluorescence and minimal cell clumping. 
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Figure 15. Computer analysis of a DNA distribution of 
TPB-dispersed Sl02F tumor cells. The solid lines 
represent computer drawn fits to the Gl peak, G2 + 
M peak, and S phase portion of the histogram. The 
fraction of the tumor cell population in GI' S, and 
G2 + M is shown in the upper right-hand corner. The 
modal channel number and coefficient of variation (C.V.) 





































































































































































Figure 16. Inhibition of deoxyuridine incorporation 
into the DNA of Sl02F tumors by FT and FU. Each data 
point and vertical bar represents the mean + S.E. of 
15-20 samples obtained from treated animals. The area 
enclosed by the dashed lines indicates the mean + S.E. 
of 15-20 control animals . 
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Figure 17. Inhibition of 3H-deoxyuridine incorporation 
into the DNA of the small intestine of SlOlF tumor-
bearing animals. The intestine were taken from mice 
bearing the Sl02F tumors represented in Figure 16. 
Each data point represents the mean + S.E. of 15-20 
samples obtained from treated animals. The area bor-
dered by the dashed lines encloses the mean + S.E. of 
15-20 control animals . 
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Figure 18. Inhibition of 3H-deoxyuridine incorporation 
into the DNA of Slow tumors by FT and FU. Each data 
point and vertical bar represents the mean + S.E. of 
15-20 samples obtained from treated animals. The area 
bordered by the dashed lines encloses the mean + S.E. 
of 15-20 control samples. 
~ FT (100 mg/kg) 
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Figure 19. Inhibition of 3H-deoxyuridine incorporation 
into the DNA of the small intestine of Slow tumor-
bearing animals. The intestines were taken from mice 
bearing the tumors shown in Figure 18. Each data point 
represents the mean + S.E. of 15-20 samples obtained 
from treated animals. The area bordered by the dashed 
lines encloses the mean + S.E. of 15-20 control samples. 
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Figure 20. Inhibition of 3H-deoxyuridine incorporation 
into the DNA of Sl02F tumors by large doses of FT and 
FU. Each data point represents the mean + S.E. of 
12-18 samples. The area bordered by the dashed lines 
encloses the mean + S.E. of 15-20 control samples. 
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Figure 21. Phase contrast photomicrograph of an un-
stained intestinal epithelial cell suspension. Villus 
cells are distinguished by their distinct brush borders. 
Crypt cells lack microvilli and show a high nuclear to 
cytoplasmic ratio. 
125 
Figure 22. Phase contrast photomicrograph of an 
epithelial cell suspension stained for leucine amino-
peptidase activity. 
(a) Cell preparation as viewed under the light 
microscope. A round crypt cell is lo-
cated between several hemi-ellipsoid villus 
cells. 
(b) Same cells viewed under fluorescent illum-
ination. The villus cells are seen to 
fluoresce brightly, whereas the crypt cell 




Figure 23. Two variable FCM analysis of an epithelial 
cell suspension stained for leucine aminopeptidase 
activity. Linear amplification of enzyme fluorescence 
is represented on the x-axis, low-angle (0-7°) forward 
scatter on the y-axis, and cell counts on the z-axis. 
(a) Isometric plot 








: • . 
If 
• 
· .. . .. 
. .... ... .. . 
· • 
.. . ..... .... . 
• 
• ••• I' • •••• • • 
•• •• •••• • · .,.. .... 
• •••• til • • ••• • •• 
• • • ••• • ••••• 
• ••• ••••••••••••• 
• • ••• ••• •••••• •• • 
• ••• • •••• •••••• • ••• 
• •••••••••••••••••• 
•• •• •••••• I. •••• ••• •• 
••• •••• ••• • •••••••••• 
••• • •••••••••••••••••• . . ........ -............ . 
• • •••••••••••••••••••••••• .. ....... .............. ... . 
.. .. .. . .................. . 
.. . ...................... . 
• ••••• ••• •••••••••• • •• • . . .. ........................ . 
.............................. 
. .... . ..................... . 
· ...................... . 
.. .......................... _. 
.. . ............ , ..... -..... . 
. ... . ......................... . 
• •••• 5 ........................ . 
•• I" •••••••••••••••••••••• - ••• 
. . ................................ . 
· ... ............................ . 
• . . . . ................... _ ...... . .. . ............................... . 
· .. . ............... -............ .. 
.. . . .............................. . 
. . . .. ..... . ...... -................. . • • ·1. . ................................ . 
... .. ................................. . 
.. .. ... ............................. . 
.. . .. . ... . ................................ . 
...... .' . .. ................................ . 
.... .... .... ... . ......................... . 
..•....... ..... . .... . .••...•..•....•.•............... 
... ......... .. .... .. . ............................. . 
· ......... ...... ....... .. . ...............•............• 
· ........ .............. . ................................ -
...................................................... I •••• 
.....•. ................ ............ ..... .... ..... ...•...... 
.................................. ............ ,., ......... . 
••• ................................................. f ••••••• 
. ...... . ..................................... " .. '" .... . 
.. . .•.................................•...•......... 
... . .................................... "" ......... . 
•• .................................... I ......... . 
. .. ...•••.•.••.•... _ ..... , •.•••.........•• 
.. . ...................... " ........ " ..... . 
• •• ................... ••••• I ••••••• 
• • ...... " ••••• ,." ......... t 
I • • "'" •• '''.1 •• , f" 
•••••••••• ,' "t •• 
........ , .. ', .. 




Figure 24. Two variable analysis by the FCM of a 
leucine aminopeptidase-stained intestinal epithelial 
cell suspension. Logarithmic amplification was uti-
lized to view enzyme fluorescence (x-axis) and low-
angle (0-7°) forward scatter (y-axis). Cell counts 
(linear amplification) are represented on the z-axis. 
(a) Isometric plot 
(b) Contour plot 
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Figure 25. Photomicrographs of sorted crypt and villus 
populations. Crypt and villus cells were separated on 
the basis of leucine aminopeptidase activity as des-
cribed in the text. Electronic cell sorting was per-
formed on cells comprising tne histogram shown in Figure 
24. Prior to cell isolation, the mice received a 30 
minute pulse of 3H- TdR to label the proliferating cells 
in S phase. 
(a) Hematoxylin- and eosin-stained villus cells. 
(b) Hematoxylin- and eosin-stained crypt cells. 
Labeled cells are seen in the center of the 
field. No labeled cells were found in the 
























Figure 26. Two-variable analysis of an epithelial cell 
suspension stained under more optimal reaction condi-
tions (as described in Methods section) for leucine 
aminopeptidase activity. Logarithmic amplification of 
enzyme fluorescence and low-angle (O-7°) forward scatter 
are represented on the x- and y-axis, respectively. 
Cell counts are shown on the z-axis. 
(a) Isometric plot. 
(b) Contour plot. 
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